NASDAQ · CING
Cingulate Inc.
$5.19-$0.06 (-1.14%)
Cingulate Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.35% below the high.
Loading market information…
AMEX · AEON · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
AEON Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 79.72% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
AEON Biopharma, Inc.’s next earnings report is currently expected on Nov 13, 2026, with estimated earnings per share of -$0.10. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow AEON Biopharma, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:13 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Mar 24, 2025 |
| $3.75+128.96% vs estimate |
| $0.00 |
| Q3 2024 | Nov 13, 2024 | -$11.510.0% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$5.19-$0.06 (-1.14%)
Cingulate Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.35% below the high.
$3.90-$0.13 (-3.23%)
Clene Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.11% below the high.
$1.01+$0.01 (+1.0%)
Marker Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.94% below the high.
$6.36-$0.22 (-3.34%)
Bolt Biotherapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.25% below the high.
$1.22-$0.02 (-1.61%)
Cellectar Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 74.04% below the high.
$8.26-$1.44 (-14.84%)
Aptorum Group Limited’s quoted price sits in the lower half of its reported 52-week range, 81.52% below the high.
$0.12$0.00 (0.0%)
OSR Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 87.17% below the high.
$0.39+$0.03 (+9.0%)
Mustang Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 73.66% below the high.
